Research and Markets (http://www.researchandmarkets.com/research/qbfxdw/antibiotic)
has announced the addition of the "Antibiotic
Resistance: Market Developments, Growth Areas and Opportunities 2014"
report to their offering.
This report provides a wealth of information for companies and
Government departments working in this field, and through a detailed
analysis of the study's findings, identifies commercial opportunities
and provides insights, which will help to guide decision-making in this
Threats posed by the global increase in antibiotic resistant bacterial
strains continue to cause alarm, and some observers suggest that this
problem is threatening to take societies back to a pre-antibiotic era.
However, the last five years have seen important changes in practices,
innovation and attitudes, in response to this growing threat. Biopharm
Reports has recently carried out a global market study of antibiotic
resistance, to identify the changing developments and management
strategies that are taking place, and the opportunities these offer to
developers i this field.
While the emergence of MRSA has embodied concerns over the rise of
antibiotic resistance, other trends are becoming increasingly
problematic. An example is the emergence of carbapenem resistance in K.
pneumonia, due to a lack of alternative treatment options. Reports from
the US suggest that 50-60% of all hospital-acquired infections are
caused by antibiotic resistant bacteria, illustrating the human and
financial impact of antibiotic resistance. In 2009, the World Health
Organisation reported that in Europe 25,000 people die every year from
drug-resistant infections. In the same year there were 440,000 new cases
of MDR tuberculosis, in 69 countries.
A competitive market analysis of current practices and future
developments across 25 key areas relating to antibiotic resistance.
- Diagnostics: Therapeutic areas, top Gram positives, Gram negatives and
other pathogens; current and future development of companion
diagnostics, tests to distinguish between bacterial and viral
infections, the identification of causal bacterial pathogens, bacterial
identification methods, preferred tests and instrumentation, preferred
suppliers, integrated and antimicrobial stewardship programmes,
requirements for innovation, new initiatives and barriers to success.
- Clinical: Therapeutic areas, top infection types, the major Gram
positives, Gram negatives and other pathogens; distinguishing bacterial
and viral infections, test costs and test times per patient, the
identification of causal bacterial, preferred methods and suppliers, the
identification of antibiotic resistance genes, integrated and
antimicrobial stewardship programmes, requirements for innovation, new
initiatives, barriers to success and future plans in these areas
- Suppliers: Who are the major company suppliers in the antibiotic
resistance' market and who do diagnosticians and clinicians plan to
purchase from over the next three years. Who are the top ten suppliers
in this field, and what changes are predicted in three years from now.
- Opportunities: The findings of this study are analysed to identify
opportunities to suppliers in the antibiotic resistance' market, in each
of the 'Diagnostics', Clinical' and Laboratory' areas indicated below.
For more information visit http://www.researchandmarkets.com/research/qbfxdw/antibiotic
[ Back To NFVZone's Homepage ]